CEL-SCI Corporation released a video presentation in which the Company's CEO, Geert Kersten, shares the most recent data presented at the European Society for Medical Oncology (ESMO) Congress and the data's impact on propelling the Company's immunotherapy drug Multikine (Leukocyte Interleukin, Injection) toward regulatory approval for the treatment of newly diagnosed, advanced squamous cell carcinoma of the head and neck (SCCHN). Mr. Kersten carefully explains how it is that patients in the target group who were treated with Multikine had a 5-year survival rate of 73% as compared to only 45% for those who did not receive Multikine, cutting the risk of death by half. He goes on to present CEL-SCI's regulatory submissions plan and timelines based on these compelling findings for a patient population that has not had a new treatment approved in the U.S. in many decades.

Summary of Multikine Results in the Target Population: 73% survival for Multikine vs 45% in the control at 5 years; 28% absolute survival benefit; Statistically significant p=.0015 and hazard ratio = 0.35; Tumor reduction rate >13% and tumor downstaging >35%; No safety signals or toxicities vs standard of care; Target population of an estimated 145,000 patients (global, annual) who present with: No nodal involvement and no extracapsular spread; Low PD-L1 tumor expression (different from high PD-L1 targeted by checkpoint inhibitors); Physicians routinely assess these features at baseline; no extra tests needed; These features make it easy to write a label for the approval of Multikine, which is essential for drug approval.